In this installment of the Leadership Perspectives series, we speak with some of the top Medical Affairs leaders from Johnson & Johnson as they think about the rapid new ascension of Medical Affairs into a fully integrated strategic business partner.
MAPS speaks with Ariel Katz, co-founder and CEO of H1, about the factors driving the evolution of Medical Affairs and look at the shape of the function in 2030 and beyond.
This 2021 Benchmark Report is based on findings from 21 leading industry organizations regarding their organizational structure, budget, and operations.
In this dynamic and conversational webinar, we will review how adaptive connected technology and processes support our mandate to deliver integrated evidence that articulates clear clinical and economic value to improve patient experience and outcomes.
Murali Gopal, MD, discusses the power of Integrated Brand Planning to transform the Medical Affairs function within the biopharmaceutical industry
Sawyer is making it her life’s work to focus on the patient—the most important stakeholder in drug development.
MAPS speaks with Beat Sümegi, SVP Medical with Sanofi, about major areas of change and the need to help Medical Affairs professionals build new skills to succeed in this world of increased responsibility and opportunity.
Eileen Sawyer, VP, Global Medical Affairs at uniQure, describes the importance of Medical Affairs acting as a strategic partner, how to effectively engage patients throughout the drug development process, and to ultimately achieve better patient outcomes.
In My Journey: The Rise & Rise of Medical, Dr. Ameet Nathwani discusses the need to define and measure our contribution, and why we need to join together as a community to shape the future of healthcare.